que la mortalidad a largo plazo esté relacionada sobre todo con la recidiva de la enfermedad actuaciones en una guía de seguimiento del paciente trasplantado. . documento recoge recomendaciones farmacoterapéuticas, de autocuidado, de . de las guías. • Algunos pacientes pueden comenzar con una diabetes de. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2 clínica, se obtuvo información sobre medicamentos antidiabéticos utilizados, dosis, .. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Objetivos: Realizar un seguimiento farmacoterapéutico y educar a pacientes conocimiento sobre la menopausia y la THR en pacientes menopaúsicas. Keywords: Hormone . ministerial que generará Guías Clínicas y tratará . stock de éste por el laboratorio que los produce. Diabetes. 38%. Depresión.

Author: Douzuru Dougami
Country: Djibouti
Language: English (Spanish)
Genre: Love
Published (Last): 14 February 2008
Pages: 108
PDF File Size: 5.36 Mb
ePub File Size: 5.27 Mb
ISBN: 547-7-11950-480-6
Downloads: 35699
Price: Free* [*Free Regsitration Required]
Uploader: Kimuro

Some treating physicians do not follow the guidelines for treatment of diabetes mellitus and do not make opportune requests for paraclinical and medical exams necessary for the complete analysis in pharmacotherapeutical monitoring.

Problemas de proceso y resultado relacionados con los medicamentos: A total of 41 pharmaceutical interventions were conducted, 35 were accepted and 6 were not accepted. Renal, ophthalmic, neurological, and vascular peripheral complications are very important in patients with type-2 diabetes, which contrasts with that found in the study, with scarce request for important tests like measurement of microalbuminuria, serum creatinine, lipid profile, and eye exam During the study, the patients were visited on at least three instances, establishing the NOMs in each visit.

The most prevalent co-morbidities were hypertension, dislipidemia, and hypothyroidism and the most frequent long-term complications can be seen in Table 2.

Seguimiento farmacoterapéutico en pacientes con insuficiencia renal crónica

Finally, it must be stated that the results are only applicable to populations of diabetic patients with similar characteristics who are affiliated to the contributive healthcare regime of Colombia’s General System of Health and Social Security. The study initially had patients, in the intervention group and in the control group, but during the course of the study 80 patients were lost from the sample because of different causes, ending the study with patients NOM are classified into problems of necessity, effectiveness, and safety; necessity NOM include untreated health problems and the effects of unnecessary medications, effectiveness NOM include the quantified and non-quantified ineffectiveness, and safety NOM include quantified and non-quantified lack of safety 9 Problemas relacionados con los medicamentos como causa de consulta en el Servicio de Urgencias del Hospital Universitario Virgen de las Nieves de Granada.


The high frequency of the necessity NOM This shows the importance of this public health problem, and its major clinical, social and economic consequences, which are associated with Chronic Kidney Disease. The design was Quasi-experimental, so that variables would not be intentionally modified, but interventions could be conducted that modified the final out-come of pharmacological treatment in patients.

Statistical Analysis The outcomes of the pharmaceutical interventions in the study were statistically analyzed with the STATA program version One of the options to prevent NOMs is through education, which was a key factor for developing this study, because it generated higher trust among health professionals, patients, and the Pharmacist.

Universidad de Granada Grupo de Investigación en Atención Farmacéutica [WorldCat Identities]

The distribution of the different study and sociodemographic variables can be seen in Table 1. Guide sobree drug dosage in renal failure. In total, 47 patients accepted to enter the PCP program; 21 of them were men and 26 were women. It is calculated that by there will be million diabetics in the world and million of these will live in our continent 1 – 3.

Of these 6 non-accepted interventions, 3 health problems were not solved, 12 dose readjustments were conducted, with cefepime as the drug with the highest number of dose adjustments; most patients were in Stage III and V of CKD, and its main cause was hypertension and Diabetes Mellitus II. The inability by patients to excrete drugs that are eliminated through the kidneys can lead to a build-up or metabolites, in case of repeated administration.

This was followed by Group A, Alimentary Tract, with prescriptions, and Group B, Blood and blood forming organs, with prescriptions; these two groups were the most widely used in all patients, due to their prophylactic nature. After identifying NOM in each patient, the pharmacist suggested for the patients in the intervention group activities to solve the health problem associated to medication use, socializing said activities with the healthcare team through a written documment.

The authors manifest and declare having no conflict of interest.


In order to ensure patient safety as a component of quality of care 7Pharmaceutical Care Practice PCP must be conducted as a clinical activity within Pharmaceutical Care PCwith the objective of reducing the morbimortality associated with the use of medications, through activities performed by the Pharmacist, who will be responsible for identifying the needs of the patient regarding pharmacological treatment, with the aim to achieve results that will improve the quality of life of patients, working together with the healthcare team in order to make decisions about the treatment initiated, to ensure its safety and efficacy 8.

Only 39 patients In terms of ethnicity, 13 patients were white, 5 patients were black, and 29 were of mixed race. After the farmacotetapeutico, the number of Sobrd was reduced to 9 in 8 patients in total, which means that 22 patients did not present DRPs again, and Upon changes in medication, a new condition status was established, which also evaluated the acceptance or non-acceptance of the physician’s pharmaceutical recommendations.

Additionally, we sought to determine the costs of caring for these patients during the study period. Diabetes Metab Res Rev.

Universidad de Granada Grupo de Investigación en Atención Farmacéutica

Pharmacotherapeutic records were the primary source of information and the secondary sources were the clinical histories, the status of the condition, records of medications dispensed by quantities and costs, along with the data base from the EPS services with the records of services rendered to their users, appointments with their treating physicians, authorizations for paraclinical exams requested by the physicians, among others.

Safety was the NOM with the highest number of reports in terms of Non-Quantitative Insecurity, which means that in this case, dosing was not a factor triggering this NOM.

Patients were handed an Informed Consent for accepting or not. This study did not reveal increased effectiveness in treatment of patients with type-2 diabetes mellitus, which also occurred in the study by Beney et al. Reduction of the therapeutic effects of some drugs such as thiazide diuretics.